Image
Insights
In-depth articles and expert analysis from pharmaceutical leaders, exploring advances in life sciences, drug development and the trends shaping healthcare innovation.
Image
Can AI and Machine Learning in Sterile Manufacturing Improve Quality?
Image
Optimising Clinical Trial Data Collection for Better Decisions
Image
What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others
Biomedical R&D
Image
Can Large Language Models Solve More Rare Disease Genomes?
AI & Machine Learning
Image
Can Large Language Models Solve More Rare Disease Genomes?
AI & Machine Learning
Image
Modular Pharma Factories: The Next Step for Continuous Manufacturing?
Continuous Manufacturing
Explore All Insights
Browse our complete library of expert articles and analysis. Explore content across science, policy and life sciences innovation.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Foundational AI In Cell and Gene Therapy Development Success
Discover why AI in cell and gene therapy is necessary for successful development by improving drug discovery, viral vector engineering, manufacturing, and quality control.
Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Claude Science: An Operating System for AI-Driven Pharma R&D
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
Europe’s Life Sciences Strategy. A New Era of Innovation?
The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Digital Measures in Clinical Trials: FDA vs EMA Pathways
Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.
FDA Draft Guidance on Gene Editing Safety (2026)
The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.
Could Biological Age Become Pharma's Most Important Biomarker?
New research shows biomarkers of biological age predict mortality and hospitalisation better than chronological age, opening new opportunities for pharma innovation.
